The purpose of this trial is to determine the safety of rituximab for the treatment of bullous pemphigoid. Secondary clinical endpoints include the number of days to cessation of new blister formation, the ability to reduce prednisone to 25% of…
- Accueil
- Qui sommes-nous
- Vivant avec P/P
- Recherche
- Impliquez-vous
- Actualités & Info
- Forums de discussion
